HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Conrad, P. W. Articles by Beitner-Johnson, D. Search for Related Content PubMed PubMed Citation Articles by Conrad, P. W. Articles by Beitner-Johnson, D. Social Bookmarking                      What's this?

J Biol Chem, Vol. 274, Issue 33, 23570-23576, August 13, 1999

Selective Activation of p38 and p38 by Hypoxia
ROLE IN REGULATION OF CYCLIN D1 BY HYPOXIA IN PC12 CELLS^*

P. William Conrad, Randall T. Rust, Jiahuai Han, David E. Millhorn, and Dana Beitner-Johnson^§

From the Department of Molecular and Cellular Physiology, College of Medicine, University of Cincinnati, Cincinnati, Ohio 45267-0576 and the  Department of Immunology, The Scripps Research Institute, La Jolla, California 92037

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Hypoxic/ischemic trauma is a primary factor in the pathology of a multitude of disease states. The effects of hypoxia on the stress- and mitogen-activated protein kinase signaling pathways were studied in PC12 cells. Exposure to moderate hypoxia (5% O₂) progressively stimulated phosphorylation and activation of p38 in particular, and also p38, two stress-activated protein kinases. In contrast, hypoxia had no effect on enzyme activity of p38, p38₂, p38, or on c-Jun N-terminal kinase, another stress-activated protein kinase. Prolonged hypoxia also induced phosphorylation and activation of p42/p44 mitogen-activated protein kinase, although this activation was modest compared with nerve growth factor- and ultraviolet light-induced activation. Hypoxia also dramatically down-regulated immunoreactivity of cyclin D1, a gene that is known to be regulated negatively by p38 at the level of gene expression (Lavoie, J. N., L'Allemain, G., Brunet, A., Muller, R., and Pouyssegur, J. (1996) J. Biol. Chem. 271, 20608-20616). This effect was partially blocked by SB203580, an inhibitor of p38 but not p38. Overexpression of a kinase-inactive form of p38 was also able to reverse in part the effect of hypoxia on cyclin D1 levels, suggesting that p38 and p38 converge to regulate cyclin D1 during hypoxia. These studies demonstrate that an extremely typical physiological stress (hypoxia) causes selective activation of specific p38 signaling elements; and they also identify a downstream target of these pathways.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Mammalian cell function is critically dependent on a continuous supply of oxygen. Even brief periods of oxygen deprivation (hypoxia/ischemia) can result in profound cellular and tissue damage. Thus, it is vital that organisms meet changes in O₂ tension with appropriate cellular adaptations; however, the specific intracellular pathways by which this occurs are not well delineated. The stress- and mitogen-activated protein kinase (SAPK¹ and MAPK) pathways play a critical role in responding to cellular stress and promoting cell growth and survival (1, 2). We therefore investigated the effect of hypoxia on the SAPK and MAPK signaling pathways.

SAPKs and MAPKs are the downstream components of three-member protein kinase modules (3). Five homologous subfamilies of these kinases have been identified, and the three major families include p38/SAPK2/RK, JNK/SAPK, and p42/p44 MAPKs/ERKs (1-6). In general, the stress-activated protein kinases (p38 and JNK) are activated primarily by noxious environmental stimuli such as ultraviolet light, osmotic stress, inflammatory cytokines, and inhibition of protein synthesis (7-10). However, increasing evidence suggests that, at least under certain conditions, these pathways can also be activated by mitogenic and neurotrophic factors (11, 12). In contrast, p42/p44 MAP kinases are stimulated primarily by mitogenic and differentiative factors in a Ras-dependent manner (5, 13, 14), although these enzymes can also be activated by certain environmental stressors (1-3). Thus, we hypothesized that hypoxia, a prevalent physiological stressor in many disease states, may regulate the activity of the SAPK and MAPK signaling pathways.

The pheochromocytoma cell line PC12 is a catecholaminergic, excitable cell type that has been used widely as an in vitro model for neural cells (15). Upon prolonged exposure to nerve growth factor (NGF), PC12 cells decrease proliferation and extend neurite-like processes (15). It has also been shown that PC12 cells are an O₂-sensitive cell type that provides a useful system to study the effects of hypoxia on catecholaminergic gene expression (16-21). PC12 cells are exquisitely sensitive to hypoxia in that very small reductions in atmospheric O₂ (from 21 to 15% O₂) dramatically induce tyrosine hydroxylase gene expression and mRNA stability (16, 17). Hypoxia also induces activation of the cAMP response element-binding protein (CREB) and c-fos transcription factors in this cell type (17, 20, 21). In addition, PC12 cells tolerate moderate hypoxia well in that they maintain greater than 95% cell viability for up to 72 h of exposure to hypoxia (5% O₂, ~50 mm Hg) (22). Finally, PC12 cells also express hypoxia-regulated ion channels, as shown by the finding that PC12 cells depolarize during hypoxia via an oxygen-regulated K⁺ current (23, 24) and secrete dopamine and norepinephrine (25, 26). Thus, this cell type is an ideal system in which to study regulation of intracellular signaling systems by hypoxia.

In the current studies, we have used this cell line to investigate the effect of hypoxia on the SAPK and MAPK signaling pathways. We show that hypoxia selectively activates the p38 and p38 isoforms of the p38 pathway in this cell type. The p38 subtype in particular is most strongly targeted by hypoxia. Furthermore, we identify cyclin D1, a gene that has been shown previously to be regulated by p38 (27), as a downstream target of hypoxia-induced activation of both p38 and p38.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Reagents and Antibodies-- SB203580 and NGF were obtained from Calbiochem. Anisomycin, sorbitol, and anti-FLAG M2 antibody were obtained from Sigma. Anti-p38 (C-20), anti-JNK1 (C-17), and anti-ERK2 (C-14) antibodies, protein G-coupled agarose for immunoprecipitations, and anti-cyclin D1 (C-20) antibodies for Western blotting were from Santa Cruz Biotechnology (Santa Cruz, CA). Protein A-coupled Sepharose was obtained from Amersham Pharmacia Biotech. MAPKAP kinase-2 assay kits and myelin basic protein were from Upstate Biotechnology, Inc. (Lake Placid, NY), and c-Jun (1-79) was from Santa Cruz Biotechnology. Phospho- and total p38 and phospho- and total p42/p44 MAPK antibodies were obtained from New England Biolabs (Beverly, MA). All cell culture media and reagents were obtained from Life Technologies, Inc.

Cell Culture-- PC12 cells were cultured in Dulbecco's modified Eagle's medium/Ham's F-12 medium supplemented with 20 mM HEPES (pH 7.4), 10% fetal bovine serum, and with penicillin (100 units/ml) and streptomycin (100 µg/ml). Prior to experimentation, cells were grown to approximately 85% confluence in 35- or 60-mm tissue culture dishes (Corning) in an environment of 21% O₂, 5% CO₂, balanced with N₂. Hypoxia was achieved by exposing cells to 5% O₂, 5% CO₂, balanced with N₂ for various times in an O₂-regulated incubator (Forma Scientific, Marietta, OH). In previous studies, we have shown that the partial pressure of O₂ in the media of cells exposed to 5% O₂ is in the range of 50-55 mm Hg (16).

Stable PC12 cell lines were created by transfecting cells with either FLAG-tagged p38AF in pcDNA3 (28) or the empty pcDNA3 vector, using Trans-Fast reagent (Promega, Madison, WI), at a charge ratio of 1:1, according to the manufacturer's recommended conditions. Individual clones expressing the kinase-inactive form of p38 (p38AF) were selected in the presence of G418 (0.4 mg/ml). Clones were screened for p38AF expression by immunoblotting whole cell lysates with an anti-FLAG antibody, as described below.

Western Blotting-- After exposure to hypoxia, cells were washed with ice-cold phosphate-buffered saline (PBS) and harvested by adding 0.2 ml/35-mm dish of a lysis buffer containing 10 mM Tris (pH 7.4), 1% Triton X-100, 0.2 mM sodium vanadate, 10 mM sodium fluoride, 1 mM EDTA, 1 mM phenylmethanesulfonyl fluoride, 2 µg/ml leupeptin, and 2 µg/ml aprotinin. Lysates were sonicated for 1 s with a microultrasonic cell disrupter (Kontes, Vineland, NJ) and then centrifuged for 10 min at 14,000 × g at 4 °C to remove the Triton-insoluble fraction. The protein concentration was determined by the method of Bradford (Bio-Rad), and gel samples were prepared by adding sample buffer containing final concentrations of 50 mM Tris (pH 6.7), 2% SDS, 2% -mercaptoethanol, and bromphenol blue as a marker. Gel samples were boiled for 2 min, and then 20-100 µg of protein was loaded on 7.5% or 9% SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose membranes (Schleicher & Schuell) using standard electroblotting procedures. Nitrocellulose membranes were blocked with 5% nonfat dry milk or 5% bovine serum albumin, for phosphotyrosine immunoblots. Blocking solutions were prepared in a buffer containing 10 mM sodium phosphate (pH 7.2), 140 mM NaCl, and 0.1% Tween 20 (PBST).

Blots were immunolabeled overnight at 4 °C with antibodies recognizing the dual phosphorylation motif at Thr¹⁸⁰ and Tyr¹⁸² of p38 (1:500) or with an antibody that equally recognizes phospho-and dephospho-p38 (1:3,000). The phosphorylation state of p42/p44 MAPK was evaluated using an antibody that specifically recognizes phospho-Tyr²⁰⁴ MAPK (1:1,000) or an antibody that equally recognizes phospho- and dephospho-MAPK (1:1,000). Cyclin D1 expression was analyzed using an anti-cyclin D1 antibody (1:2,500). FLAG-tagged p38 protein kinases were detected with an anti-FLAG M2 monoclonal antibody (1:500). Immunoblots were washed in several changes of PBST at room temperature and then incubated with anti-rabbit Ig linked to horseradish peroxidase or, for FLAG and cyclin D1, an anti-mouse Ig linked to horseradish peroxidase (Amersham Pharmacia Biotech). Immunoreactivity was detected with enhanced chemiluminescence (Amersham Pharmacia Biotech) according to the manufacturer's recommended conditions and quantified using densitometric analysis with an ImagePro digital analysis system (Media Cybernetics, Silver Springs, MD). Immunoreactivity for all proteins evaluated was linear over at least a 3-fold range of protein concentrations.

Immune Complex Kinase Assays-- For MAPK and SAPK assays, cells were grown to 70% confluence on 35-mm tissue culture dishes. For p38 kinase assays, cells on 35-mm dishes were transiently transfected with 5 µg of FLAG-p38, FLAG-p38, FLAG-p382, FLAG-p38, FLAG-p38, or pcDNA3, using Trans-Fast reagent at a charge ratio of 1:1, according to the manufacturer's recommended conditions. These constructs have been described previously (5, 28-30). Cells were then exposed to normoxia, hypoxia, or UV light (300 J/m²), or sorbitol (300 mM) 48 h after transfection. Cells were then washed with ice-cold PBS and harvested by adding 0.3 ml of buffer A (50 mM Tris (pH 7.4), 2 mM EDTA, 2 mM EGTA, 0.5 mM sodium vanadate, 10 mM -glycerophosphate, 1% Triton X-100, 1 mM phenylmethanesulfonyl fluoride, 2 µg/ml leupeptin, 2 µg/ml aprotinin, and 0.1% (v/v) -mercaptoethanol). Cell lysates were centrifuged for 10 min at 14,000 × g at 4 °C to pellet the Triton-insoluble fraction. FLAG-tagged p38 isoforms were immunoprecipitated from 200 µg of total cellular protein using 10 µg of anti-FLAG M2 monoclonal antibody coupled to agarose and followed by rocking at 4 °C for 2-24 h. Immunoprecipitation of MAPK or JNK was achieved by adding 0.5 µg of ERK2 or 1 µg of JNK antibody to lysates containing 500 µg of total cellular protein and rocking at 4 °C for 2-4 h. 50 µl of a 10% (w/v) suspension of protein A-Sepharose beads was then added, and the reaction slurry was allowed to rock at 4 °C for 2-24 h. The immunoprecipitation complex was washed twice with 0.5 ml of ice-cold fresh buffer A, twice with PBS, and twice with kinase assay buffer (containing 20 mM MOPS (pH 7.2), 25 mM -glycerophosphate, 5 mM EGTA, 1 mM sodium orthovanadate, and 1 mM dithiothreitol). In addition to buffer A described above, the kinase assay reaction mixture contained final concentrations of 7.5 mM MgCl₂, 50 µM ATP containing 20 µCi of [-³²P]ATP and either 10 µg of myelin basic protein for p38 and p42/p44 MAPK assays, or 10 µg of c-Jun (1-79) for JNK assay, in a final volume of 100 µl. Reactions were initiated by the addition of 10 µl of [-³²P]ATP (NEN Life Science Products) and incubated for 20 min shaking at 30 °C. Reactions were stopped by the addition of Laemmli SDS sample buffer containing -mercaptoethanol and bromphenol blue. Samples were boiled for 2 min and run on either 15% SDS-polacrylamide gels for analysis of p38 and p42/p44 MAPK or 9% SDS-polyacrylamide gels for JNK enzyme activity. Kinase activity was measured as the amount of ³²P incorporation into the specific substrate proteins as quantified by PhosphorImager analysis (Molecular Dynamics, Sunnyvale, CA). MAPKAP kinase-2 assays were performed essentially as described previously (20) except that cell lysates were rapidly frozen in a dry ice/ethanol bath to facilitate cell lysis. Lysates were then thawed and processed for MAPKAP kinase-2 activity using an immunoprecipitation kinase kit (Upstate Biotechnology Inc.) according to the manufacturer's recommended conditions.

Flow Cytometry-- Flow cytometry was performed as described previously (31). PC12 cells were grown to approximately 70% confluence on 35-mm tissue culture dishes. After normoxic or hypoxic treatment for 24 h, cells were harvested by adding 150 µl of 0.05% trypsin. 1 ml of a solution containing 10% fetal bovine serum in PBS was added to quench the trypsin. Cells were then centrifuged and resuspended in 100 µl of a freezing buffer containing 250 mM sucrose, 5% dimethyl sulfoxide, and 40 mM sodium citrate. Cells were stored at 80 °C until preparation for flow cytometry. 50 µl from each cell sample was aliquoted and then lysed by the addition of 100 µl of a solution containing 0.5% Nonidet P-40 and 0.5 mM EDTA in PBS. 1 µl of RNase (10 mg/ml, Qiagen, Santa Clarita, CA) was also added, and the cell mixture was then rocked for 15 min at room temperature. The samples from each tube were added to 1 ml of a solution containing 50 µg/ml propidium iodide in PBS. Samples were analyzed on a Coulter Epics XL (Beckman-Coulter Co., Miami, FL) and analyzed using a WinCycle software package (Phoenix Flow Systems, San Diego).

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Hypoxia is an extremely common physiological stressor. To investigate the effects of hypoxia on the stress- and mitogen-activated signaling pathways, PC12 cells were exposed to 5% O₂ for various times, between 20 min and 6 h. Whole cell lysates were subjected to SDS-polyacrylamide gel electrophoresis and then immunoblotted with an antibody specific for Thr¹⁸⁰/Tyr¹⁸²-phosphorylated p38. Phosphorylation at these sites is both necessary and sufficient for enzymatic activation of p38 (5). It can be seen in Fig. 1A that exposure to hypoxia progressively induced phospho-p38 immunoreactivity in two closely migrating bands. Phospho-p38 blots were then stripped and reblotted with an antibody that equally recognizes phospho- and dephospho-p38 (i.e. total p38). Fig. 1B shows that the lower phospho-p38 immunoreactive protein shown in Fig. 1A corresponded to p38, as determined by alignment of films using luminescent markers affixed directly to the blot. As shown in Fig. 1B, hypoxia did not alter the total amount of p38 protein. Of the time points examined, maximal hypoxia-induced phosphorylation of p38 occurred at 6 h, where there was an average 4.5-fold increase in p38 phosphoimmunoreactivity (Fig. 1C). The upper phospho-p38 immunoreactive band was identified as the p38 isoform, as described below. Phosphoimmunoreactivity of p38 was increased more strongly by hypoxia, with an average of 12.7-fold increase over control levels by a 6-h exposure to hypoxia (Fig. 1C). These results suggest that both p38 and p38 are activated by hypoxia. Phosphorylation of p38 and p38 declined somewhat but was still elevated above control levels up to 24-h exposure to hypoxia (data not shown).

View larger version (30K): [in this window] [in a new window]   Fig. 1.   Effect of hypoxia on p38 and p38 phosphorylation state. PC12 cells were exposed to hypoxia (5% O2) for various times between 0 and 6 h, as indicated. Panel A, representative immunoblot illustrating the effect of hypoxia on phospho-p38 and phospho-p38 immunoreactivity. Panel B, the blot shown in panel A was stripped and reprobed with an antibody that equally recognizes phospho- and dephospho-p38. Panel C, immunoreactivity levels of phospho-p38 (black bars) and phospho-p38 (shaded bars) are expressed as average percent change from control ± S.E. and represent six dishes in each group, performed in two separate experiments. Phospho-p38 immunoreactivity was quantified by densitometry (*p < 0.01, by 2 test).

The upper phospho-p38 immunoreactive band shown in Fig. 1A was identified as p38 by stripping and reblotting with a specific antibody raised against full-length recombinant p38 (28), an isoform of p38 also known as ERK6 and SAPK3 (32, 33). Alignment of the resulting films showed that p38 comigrated exactly with the upper phospho-p38 immunoreactive protein (data not shown). Although p38 and p38 were also expressed in PC12 cells, neither of these proteins comigrated with p38, as determined using specific antibodies for the p38 and p38 subtypes (data not shown).

To characterize further the effects of hypoxia on p38 enzyme activity, PC12 cells were transfected with FLAG epitope-tagged versions of p38, p38, p38₂, p38, or p38. Cells were then exposed to either normoxia (21% O₂) or hypoxia (5% O₂, 6 h). The various kinases were then immunoprecipitated with an anti-FLAG antibody, and immune complex kinase assays were performed, as described under "Experimental Procedures." As shown in Fig. 2A, hypoxia stimulated both p38 and p38 enzyme activity. In contrast to these results, hypoxia did not significantly alter p38, p382, or p38 enzyme activity. Hypoxia-induced changes in enzyme activity were not the result of differences in transfection efficiency as cell lysates blotted with anti-FLAG show equal amounts of the transfected protein (Fig. 2B). It can be seen that the effect of hypoxia on the p38 isoform is by far the most robust (average 5.9-fold activation, Fig. 2C).

View larger version (41K): [in this window] [in a new window]   Fig. 2.   Effect of hypoxia on enzyme activity of the various p38 isoforms. PC12 cells were transfected with FLAG-p38, FLAG-p38, FLAG-p382, FLAG-p38, FLAG-p38, or the pCDNA3 vector. After 48 h, cells were exposed to either control conditions (C, 21% O2) or hypoxia (H, 5% O2, 6 h). Panel A, enzyme activity of various p38 isoforms was determined in immune complex kinase assays by the amount of 32P incorporation into myelin basic protein (mbp) as described under "Experimental Procedures." Panel B, whole cell lysates were immunoblotted for FLAG as described under "Experimental Procedures." Panel C, protein kinase activity of the various p38 isoforms after exposure to normoxia (black bars) or hypoxia (shaded bars) is expressed as average percent of control ± S.E. and represents six to nine dishes in each group, performed in at least two separate experiments.

We next evaluated the effect of hypoxia on JNK, another SAPK. PC12 cells were exposed to hypoxia for various times, from 20 min to 6 h, and JNK enzyme activity was measured in an immune complex kinase assay, as described under "Experimental Procedures." Unlike its effects on p38, hypoxia did not alter JNK enzyme activity significantly, whereas exposure of cells to UV light increased JNK activity markedly (Fig. 3).

View larger version (13K): [in this window] [in a new window]   Fig. 3.   Lack of effect of hypoxia on JNK activity. PC12 cells were exposed to either hypoxia (5% O2) for various times between 0 and 6 h, as indicated, or to 300 J/m2 UV light for 30 min. JNK was immunoprecipitated by the addition of 1 µg of anti-JNK1 polyclonal antibody as described under "Experimental Procedures." JNK enzyme activity was determined in an immune complex kinase assay by the amount of 32P incorporation into c-Jun as quantified by PhosphorImager. Similar results were found in three separate experiments representing three dishes in each group.

To determine the effect of hypoxia on p42/p44 MAPK, PC12 cells were again exposed to either normoxia (21% O₂) or hypoxia (5% O₂) for various times, between 20 min and 6 h. Samples of whole cell lysates were immunoblotted with either an antibody specific for tyrosine-phosphorylated (activated) p42/p44 MAPK or an antibody that equally recognizes phospho- and dephospho-p42/p44 MAPK (total MAPK). Hypoxia had no significant effect on the levels of phospho-p42/p44 MAPK at the earliest time points studied. However, exposure to hypoxia for 6 h caused an increase in the tyrosine phosphorylation of p42/p44 MAPK (Fig. 4, A and C). The total amount of p42/p44 MAPK was not affected by hypoxia, as shown in Fig. 4B. MAPK enzyme activity was measured directly by immune complex kinase assay. Fig. 4C shows that p42 MAPK enzyme activity, like the MAPK phosphorylation state, increased after 6 h of hypoxia. To compare the effects of hypoxia with the prototypical activators of MAPK, we also evaluated p42/p44 MAPK phosphorylation in response to NGF and UV light. In contrast to the rather modest effect of hypoxia, these stimuli caused a robust phosphorylation of p42/p44 MAPK (Fig. 4D).

View larger version (31K): [in this window] [in a new window]   Fig. 4.   Hypoxia modestly activates p42/p44 MAPK. PC12 cells were exposed to hypoxia (5% O2) for various times between 0 and 6 h, as indicated. In panels A and B, lysates were subjected to SDS-polyacrylamide gel electrophoresis and immunoblotted with antibodies specific for either Tyr204-phosphorylated p42/p44 MAPK or total (phospho- and dephospho-) MAPK, as described under "Experimental Procedures." Panel A, representative immunoblot showing phospho-p42/p44 MAP kinase immunoreactivity at the various time points studied. Panel B, representative immunoblot showing total MAPK at the various time points studied. Results similar to those shown in panels A and B were observed in three separate experiments. Panel C, MAPK enzyme activity was determined in an immune complex kinase assay by the amount of 32P incorporation into myelin basic protein as quantified by PhosphorImager. Data shown are representative of those obtained in two separate experiments and represent six dishes in each group. Panel D, representative immunoblot of Tyr204-phosphorylated p42/p44 MAPK immunoreactivity in lysates of PC12 cells exposed to normoxia (C, 21% O2), hypoxia (H, 5% O2), NGF (50 ng/ml), or 300 J/m2 UV light (30 min). Similar results were found in two separate experiments representing six dishes in each group.

The downstream transcription factors and protein kinases that are targeted by the p38 family are beginning to be elucidated (1-3, 34-43); however, very little is known about the specific genes that are regulated in response to activation of the p38 pathways. The cyclin D1 gene is one known target of p38, as Lavoie et al. (27) have shown that cyclin D1 gene expression is regulated negatively by p38 in CCl39 cells. We therefore tested whether hypoxia regulated cyclin D1 levels in PC12 cells. We found that exposure to hypoxia (0, 3, 6, or 24 h at 5% O₂) progressively down-regulated cyclin D1 levels, with an 81% decrease of cyclin D1 from control levels observed at 24 h (Table I). Pretreatment of cells with SB203580, a relatively selective inhibitor of p38 (43, 44), was able to reverse in part the down-regulation of cyclin D1 by hypoxia in a dose-dependent manner (Fig. 5A). These results are expressed quantitatively in Fig. 5B, where it can be seen that pretreatment with SB203580 resulted in a partial, but statistically significant, recovery of cyclin D1 toward control levels. The inhibitory effect of SB203580 on hypoxic regulation of cyclin D1 was observed at low doses (0.3-1 µM) as was its inhibitory effect on anisomycin-activated MAPKAP kinase-2. MAPKAP kinase-2 is a protein kinase that is specifically phosphorylated and activated by the p38 family of protein kinases (Fig. 5C). The fact that SB203580 only partially reversed the effects of hypoxia may be because this drug does not inhibit the p38 isoform (45-47), as discussed further below.

View larger version (18K): [in this window] [in a new window]   Fig. 5.   Hypoxia inhibits cyclin D1 and causes accumulation at G0/G1 via a partially p38-dependent mechanism. PC12 cells were exposed to either normoxia (C, 21% O2) or hypoxia (H, 5% O2) for 24 h in the presence or absence of increasing amounts of SB203580, as indicated. Panel A, representative immunoblot showing the effects of hypoxia and p38 inhibition on cyclin D1 immunoreactivity. Panel B, immunoreactivity levels of cyclin D1 are expressed as the average percent change from control ± S.E. and represent 6-12 dishes in each group performed in at least two separate experiments. * indicates significant difference from control, and # indicates significant difference from hypoxia plus vehicle, p < 0.05, by 2 test. Panel C, cells were exposed to either vehicle (Cntrl) or anisomycin (10 µg/ml) for 20 min, in the presence of various levels of SB203580, as indicated. MAPKAP kinase-2 enzyme activity was measured in immune complex kinase assays, as described. Panel D, cells were pretreated with vehicle or 20 µM SB203580 and then exposed to normoxia or hypoxia for 24 h. Cells were stained with propidium iodide and analyzed by flow cytometry as described under "Experimental Procedures." Data are expressed as the percent change from control ± S.E. and represent seven dishes in each group, performed in two separate experiments. * indicates significant difference from control, and # indicates significant difference from hypoxia plus vehicle, p < 0.05, by 2 test.

Cyclin D1 is a G₁ cyclin whose synthesis and associated cyclin-dependent kinase activity are generally required for progression through the G₁ phase of the cell cycle (48, 49). Our finding that hypoxia induces a down-regulation of cyclin D1 suggested that hypoxia may cause cells to accumulate in the G₀/G₁ phase of the cell cycle. We therefore evaluated the relative percentage of cells in the various phases of the cell cycle in PC12 cells that were exposed to either normoxia or hypoxia for 24 h. Cells were stained with propidium iodide and analyzed by flow cytometry. It can be seen in Fig. 5D that hypoxia caused a 17.4% increase in the number of cells in G₀/G₁. Furthermore, pretreatment with SB203580 followed by a 24-h exposure to hypoxia was able to reverse in part this accumulation in G₀/G₁.

Our results show that hypoxia activates both p38 and p38; however, the p38 isoform is insensitive to inhibition by SB203580 (45-47). This raised the possibility that p38 might also contribute to the inhibition of cyclin D1 by hypoxia (i.e. the portion of the effect that was not inhibited by SB203580). To test this hypothesis, we generated stably transfected PC12 cell lines that express p38AF, a kinase-inactive mutant of p38. Overexpression of a similar mutant (Y185F) has been shown previously to inhibit endogenous p38 enzyme activity effectively (32). Fig. 6 shows that, compared with vector-transfected cells, the hypoxia-induced decrease in cyclin D1 is partially reversed in the p38AF cell line. These results were confirmed in two separate clones and show that p38, like p38, is involved in the down-regulation of cyclin D1 during hypoxia; however, pretreatment of p38AF-expressing cells with SB203580 did not result in a further impairment of the effect of hypoxia on cyclin D1 expression (data not shown).

View larger version (20K): [in this window] [in a new window]   Fig. 6.   Role of p38 in the hypoxia-induced decrease in cyclin D1. PC12 cells stably transfected with a kinase-inactive form of p38 or the empty expression vector pcDNA3 were exposed to hypoxia for 24 h, as indicated. Panel A, representative immuoblot showing the effect of p38 inhibition on the hypoxia-induced decrease in cyclin D1. Panel B, immunoreactivity levels of cyclin D1 are expressed as average percent change from control ± S.E. and represent six dishes in each group performed in two separate experiments * indicates significant difference from control-pcDNA3, p < 0.05, by 2 test, and # indicates significant difference from hypoxia-pcDNA3, p < 0.05, by 2 test.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The signaling pathways involved in cellular responses and adaptations to hypoxia are very poorly understood. The PC12 cell line is a neural-like cell line that has been shown to respond to very small reductions in O₂ levels with changes in ion conductances (23, 24), protein phosphorylation (20, 22), and gene expression (16-21). These studies were aimed at identifying specific intracellular signaling pathways that are regulated by hypoxia in this cell type. We have shown that moderate hypoxia (5% O₂) selectively activates p38 and p38, but not other isoforms of the p38 family of SAPKs. Furthermore, activation of both p38 and p38 is involved in the down-regulation of cyclin D1 during hypoxia. In contrast, another major SAPK, JNK, was not affected by hypoxia.

The p38 family of protein kinases consists of several isoforms, including p38, p38, p382, p38/SAPK3/ERK6, and p38/SAPK4 (4, 10, 28-30, 32, 33, 45, 50, 51). These kinases are activated by a variety of stressors, including osmotic stress, UV light, inhibition of protein synthesis, and inflammatory cytokines; however, the mechanism by which these diverse stimuli activate p38 kinases is not known. Our results demonstrate, for the first time, that physiological levels of hypoxia selectively activate p38 and p38. Phosphorylation of p38 has been shown to occur after ischemia in heart and kidney (52). Taken together with our findings, it is possible that the hypoxic component of ischemia, rather than the other types of substrate depletion (glucose, ATP, etc.), results in the activation of p38 and p38.

The p38 isoform was most strongly targeted by hypoxia in PC12 cells. The molecular basis of this selectivity is not known, and in general, previous studies have found the closely related isoforms to be activated coordinately by various stressors (29, 46, 50, 51). Recent evidence suggests, however, that there may be unique physiological roles for p38. It has been shown that the carboxyl-terminal sequence -KEXTL of p38 interacts with the PDZ domain of -syntrophin, a substrate that is phosphorylated by p38 (53). Interestingly, p38 is the only member of the currently known MAPK families to have a carboxyl-terminal PDZ domain binding sequence and is likely to interact with other PDZ domain-containing proteins. Many proteins with PDZ domains are localized to specific subcellular locations, such as synapses (54, 55). p38 is enriched in skeletal muscle (28, 32, 51) but is also expressed at moderate levels throughout the central nervous system (51). Our results showing that hypoxia preferentially activates p38 in a neural-like cell line suggests possible specialized roles for this enzyme in excitable cells.

The other major stress-activated signaling pathway acts through the JNK family of protein kinases (1-3). Like p38, the JNK family is activated by a number of stressors but is distinctive in its ability to phosphorylate the transcription factor c-Jun (6, 8). It has been reported previously that ischemia/reperfusion in the kidney and hypoxia/reoxygenation in cardiac myocytes induce activation of JNK (52, 56). These groups found JNK activity to be activated by the reoxygenation event but not during the initial hypoxia or ischemia. It has also been reported recently that severe hypoxia (pO₂  0.01%) transiently activated JNK in human squamous carcinoma cells (57). In contrast, we found that neither hypoxia nor hypoxia plus reoxygenation (data not shown) between 20 min and 6 h stimulated JNK enzyme activity in PC12 cells. Clearly, various stressors can have different effects, depending on the specific cell type and its environment. The differential effects of hypoxia on p38 and JNK contribute to a small but growing number of stimuli that selectively activate p38 but not JNK (58).

Hypoxia (6 h, 5% O₂) also caused a modest activation of p42/p44 MAPK in PC12 cells. It has been reported previously that HeLa cells respond to severe hypoxia with a rapid (within 15 min) but transient activation of p42/p44 MAPK (59). In PC12 cells, hypoxia induced a relatively small and delayed activation of p42/p44 MAPK compared with the robust and rapid activation induced by NGF or UV exposure.

It is of considerable interest to determine which downstream genes are regulated by p38 and p38 in response to hypoxia. A number of downstream kinases, including MAPKAP kinase-2/3 (34, 35), MAPK signal-integrating kinase (MNK) (36), and p38-regulated/activated protein kinase (PRAK) (37), as well as transcription factors and ternary complex factors, including C/EBP-homologous protein (CHOP), switch-activating protein (Sap1), myocyte-enhancer factor 2A (MEF2A), and MEF2C have been shown to be phosphorylated and activated by the p38 family of protein kinases (38-42); however, the specific genes that are regulated in response to activation of p38 and these transcription factors remain largely unknown. One gene that has been shown to be regulated by p38 is cyclin D1 (27). Activation of p38 strongly inhibits cyclin D1 gene expression in CCL39 cells (27). Likewise, hypoxia down-regulates cyclin D1 expression in PC12 cells. We showed further that p38 is involved in this hypoxia-induced decrease in cyclin D1 levels, as the effect is partially blocked by low doses of SB203580, a relatively selective inhibitor of p38 (43, 44). The failure of SB203580 to reverse this effect completely may be because of activation of p38, which is insensitive to inhibition by SB203580 (45-47). p38 is also involved in the regulation of cyclin D1, as overexpression of a kinase-inactive mutant (p38AF) partially reverses the decrease in cyclin D1 during hypoxia. However, pretreatment of PC12 cells overexpressing p38AF with SB203580 did not result in a further reversal of the effects of hypoxia on cyclin D1 expression (data not shown). It is not clear why SB203580 would be ineffective in this cell line, but it is possible that p38AF expression could impair both p38 and p38 function. Because both p38 and p38 have been shown to have identical upstream activators (46), p38AF may sequester activated MAP kinase kinase-3 (MKK3) and/or MKK6, thereby impairing the activity of any of its downstream p38 kinases. Alternatively, the stably transfected p38AF cells, because they are cultured in the presence of the selection drug (G418) may differ from the parental cell line in a number of ways that are difficult to assess.

Cyclin D1 has been implicated in regulating progression through the G₁ phase of the cell cycle (48, 49). The hypoxia-induced inhibition of cyclin D1 correlates with an increased accumulation of cells in G₀/G₁ after exposure to hypoxia. This accumulation was also shown to be partially blocked by cotreatment of cells with SB203580. It is important to note that although there is a relative increase in the accumulation of cells in the G₀/G₁ phase, we did not observe a corresponding decrease in cell cycle progression during hypoxia. In fact, preliminary findings suggest that hypoxia may induce proliferation as measured by [³H]thymidine incorporation,² as has been reported in other cell lines (60-62). Such seemingly contradictory findings (a concomitant decrease in cyclin D1 levels with cellular proliferation) are not entirely incompatible. For example, cyclin D1 has been shown to be critical for growth factor-mediated proliferation (63). The role of cyclin D1 in hypoxia-induced proliferation, which likely proceeds via a different mechanism, is not known. In addition, hypoxia does not decrease the immunoreactivity of other major cyclins, including the S phase cyclin, cyclin A (data not shown), as would be predicted during inhibition of cell cycle progression. Furthermore, it has been shown that NGF induces cyclin D1 expression in PC12 cells (64). This increase in cyclin D1 is associated with a G₁ phase block and a decrease in proliferation, as PC12 cells begin to differentiate (65). Finally, cyclin D1 is now known to have other functions, separate from regulation of cyclin-dependent kinases. For example, cyclin D1 can associate with histone acetyltransferase, p300/CBP-associated protein (P/CAF) and facilitate estrogen receptor function (66). Thus, cyclin D1 levels do not always correlate with cell cycle progression, especially in this cell type. Clearly, further studies are required to elucidate the mechanism of hypoxia-induced regulation of cell cycle progression in PC12 cells.

Taken together, these studies demonstrate that hypoxia, an extremely typical physiological stress, causes specific regulation of the SAPK and MAPK signaling pathways. We also show that one isoform of p38, p38, is particularly strongly activated by hypoxia. This is, to our knowledge, one of the first demonstrations of selective activation of a particular subtype of a p38 family protein kinase. Furthermore, cyclin D1 levels are regulated by hypoxia via both p38 and p38. Future studies are aimed at delineating the specific mechanisms by which a reduction in O₂ levels causes regulation of these pathways.

	ACKNOWLEDGEMENTS

We thank J. Cornelius and Dr. G. Babcock for assistance with flow cytometry performed at the Shriners Hospital for Children-Cincinnati. We also thank T. Dixon for technical assistance, G. Dezutter for helpful discussions, and G. Doerman and R. Glover for preparation of figures.

	FOOTNOTES

^* This work was supported by Grant 9806242 from the American Heart Association, Ohio Valley Affiliate, and a grant from the Parker B. Francis Foundation (both to D. B.-J.), National Institutes of Health Grants R37HL33831 and RO1HL59945 (to D. E. M.), U.S. Army Grant DAMD 17-99-1-9544 (to D. E. M.), and National Institutes of Health Training Grant HL07571 (to P. W. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ To whom correspondence should be addressed: Dept. of Molecular and Cellular Physiology, College of Medicine, University of Cincinnati, P.O. Box 67-0576, Cincinnati, OH 45267-0576. Tel.: 513-558-6009; Fax: 513-558-5738; E-mail: dana.johnson@uc.edu.

² P. W. Conrad, unpublished data.

	ABBREVIATIONS

The abbreviations used are: SAPK, stress activated protein kinase; MAPK, mitogen activated protein kinase; JNK, c-Jun N-terminal kinase; ERK, extracellular signal-regulated kinase; NGF, nerve growth factor; PBS, phosphate-buffered saline; MOPS, 4-morpholinepropanesulfonic acid; PDZ, PSD-95, Discs-Large, ZO-1; RK, reactivating kinase; MAPKAP, mitogen-activated protein kinase activated protein.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore